Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals
The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years
世界衛生組織（WHO）將新克萊德Ib Mpox的傳播宣佈爲國際關注的公共衛生緊急事件（PHEIC）：這是兩年來第二次與Mpox相關的WHO PHEIC聲明
Clade Ib Mpox cases detected in 16 African countries and outside of Africa, in Sweden, Thailand, Singapore, India, Germany and England
在16個非洲國家以及瑞典、泰國、新加坡、印度、德國和英國發現了克萊德Ib Mpox病例
Single-dose mpox vaccines with durable protection may be required to address global health emergency
可能需要單劑量的mpox疫苗以提供持久的保護，來應對全球健康緊急事件
TNX-801 was shown to be more than 10- to 1,000-fold more attenuated (or less virulent) compared to the older vaccinia smallpox vaccines: Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development
與舊的水痘疫苗相比，TNX-801的減毒超過了10到1,000倍（或致病性更低）：TNX-801在免疫受損動物模型中的耐受性支持了其臨床開發
